CellWell record HH-401999
Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders
Marwan N Sabbagh; Jeffrey L Cummings; Clive Ballard; Wiesje M van der Flier; Michael T Heneka; Jens Juul Holst; Lotte Bjerre Knudsen; Stephen Salloway; Malú Gámez Tansey; Daniel J Drucker
2026
In plain language
This review found that GLP-1 receptor agonists were linked to lower dementia risk in patients with type 2 diabetes, but trials have not yet shown they slow cognitive decline in Alzheimer's disease.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-401999
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.